Cardiol Therapeutics Inc. Class A CRDL 深 沪
已收盘 10-09 16:00:00 美东时间
1.23
-0.070
-5.38%
华盛通- 最 高1.3241
- 今 开1.32
- 成交量 126.36万股
- 最 低 1.23
- 昨 收 1.30
- 总市值 1.49亿
- 52周最高 2.34
- 市盈率 静 --
- 换手率 1.04%
- 52周最低 0.88
- 委 比 18.28%
- 总股本 1.22亿
- 历史最高 4.96
- 量 比 0.40
- 振 幅 7.24%
- 历史最低 0.45
- 每 手 1
- 风险率 0.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
09-23 22:52
Cardiol Therapeutics Files $150M Base Shelf Prospectus, Enabling Future Offerings Of Shares, Debt, Warrants And Other Securities
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has filed a preliminary short form base shelf prospectus (the "Shelf Prospectus") wit...
09-11 05:02
美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $10
Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and raises the price target from $8 to $10.
08-17 20:21
美股大行评级 | 美银上调AMD目标价从550美元升至620美元；IBM暴跌25%！大摩上调目标价升至293美元，汇丰下调评级至"卖出"目标价降至191美元
今日重点评级关注：Keybanc：维持迈威尔科技"超配"评级，目标价从385美元升至400美元；丰业银行：维持科尔黛伦矿业"跑赢大市"评级，目标价从27.5美元升至28.5美元
07-15 10:22
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
07-15 01:22
Cardiol Advances Key Studies and Secures Funding to Push New Heart Treatments Forward
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease,
04-01 19:32
Cardiol Therapeutics Announces Publication Of Results From Phase II ARCHER Study In ESC Heart Failure, Journal Of European Society Of Cardiology
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease,
02-10 20:30
Cardiol Therapeutics Surpasses 50% Participant Enrollment In MAVERIC Phase III Study Of CardiolRx
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease,
01-13 20:31
